AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.

See Full Page

Interests (0)

Settings

AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin

US core PCE firms slightly but matches expectations

India's economy grows 7.8% in April

US jobs data poses test for rate-cut hopes, stocks rally

French economic growth confirmed at 0.3% in second quarter

China's factory activity seen shrinking again on soft demand, job woes: Reuters poll

US equity funds draw only subdued inflows on Fed independence risk

S&P 500 dips from record highs as Dell and Nvidia drop

HanesBrands being sold to rival Gildan for $4.4 billion in stunning apparel deal

Stocks decline, US Treasury yields rise; US inflation data mostly in line

Chipmaker Marvell's weak data center forecast prompts AI investors to dump its stock

Wednesday cast members look totally unrecognizable from their spooky characters at NYC bash with pal Lady Gaga

Silicon Motion: MonTitan And Mobile Drive Tactical Upside

Commercial Bancgroup Begins $173 Million IPO Rollout (Pending:CBK)

G Mining: Robust Self-Financing Strategy And Second Mine Building Decision Approaching

Russian Missile and Drone Attack on Kyiv Kills 18

Shooter kills two Minneapolis school children in Catholic church, wounds 17 others

The Latest: RFK Jr. adviser will serve as acting CDC leader after director’s firing, AP source says

Florida's 'Alligator Alcatraz' to Have No Detainees Soon

Judge Blocks Deportation of Kilmar Abrego Garcia

What we know about the shooter who killed 2 and wounded 18 in Minneapolis

Minneapolis Shooter Exhibited Hatred for Many Groups

Powerball Jackpot Reaches $850 Million for Tonight's Drawing

Robot Rabbits Deployed to Combat Invasive Pythons in Florida

Cracker Barrel Reverts to Old Logo After Backlash